-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 21, the State Food and Drug Administration announced the pending receipt of the drug notification, and Bayer's PI3K inhibitor copanlisib was listed
Copanlisib is an intravenously administered phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity against both PI3K-α and PI3K-δ isoforms expressed in malignant B cells, which can be inhibited by apoptosis apoptosis and inhibit the proliferation of malignant B cells to induce tumor cell death
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
According to the European Medicines Agency (EMA) website, Bayer withdrew a marketing application for copanlisib in the EU in December 2021 for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)